An advanced calcium scoring application developed by the Scottish firm Voxar has cleared the FDA. Voxar Calscreen 2.1 is designed to detect, quantify, and report the presence of calcium plaque in the coronary arteries. It complements the company's
An advanced calcium scoring application developed by the Scottish firm Voxar has cleared the FDA. Voxar Calscreen 2.1 is designed to detect, quantify, and report the presence of calcium plaque in the coronary arteries. It complements the company's flagship Plug n View 3D and Voxar Colonscreen products. The package automates the identification of calcified plaques in the coronary arteries and calculates the calcium score, providing the basis for assessing potential risk and managing associated coronary heart disease before symptoms arise. Calscreen 2.1 works with electron-beam tomography scanners and multislice or helical CTs. The package, which runs on a standard PC, automatically highlights calcified regions in red as part of multiplanar reformatted (MPR) and 3D views of the heart.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.